Aplicaciones de los cannabinoides en glaucoma

Referències bibliogràfiques

• Lastres-Becker, I, Molina-Holgado, F, Ramos, JA, Mechoulam, R, Fernández-Ruiz, J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson´s disease. Neurobiol Dis.. 19. 96-107
• Ramírez, BG, Blázquez, C, Gómez, DP, Guzmán, M, De Ceballos, ML. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci.. 25. 1904
• Panikashvili, D, Simeonidou, C, Ben-Shabat, S, Hanus, L, Breuer, A, Mechoulam, R. (2001). An endogenous cannabinoid (2AG) is neuroprotective after brain injury. Nature. 413. 527
• Amantea, D, Spagnuolo, P, Bari, M, Fezza, F, Mazzei, C, Tassorelli, C. (2007). Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J.. 274. 4464
• Centonze, D, Rossi, S, Finazzi-Agró, A, Benardi, G, Maccarrone, M. (2007). The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. Int Rev Neurobiol.. 82. 171
• Macarrone, M, Battista, N, Centonze, D. (2007). The endocannabinoid pathway in Huntington´s disease: a comparison with other neurodegenerative diseases. Prog Neurobiol.. 81. 349
• Hepler, RS, Frank, IM, Petrus, R. (1976). The Pharmacology of marihuana. Raven Press. New York^eNY NY.
• García-Valenzuela, E, Shareef, S, Walsh, J, Sharma, SC. (1995). Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res.. 61. 33-44
• Dong, CJ, Guo, Y, Agey, P, Wheeler, L, Hare, WA. (2008). Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci.. 49. 4515
• Dewey, WL. (1986). Cannabinoid pharmacology. Pharmacol Rev.. 38. 151
• Gaoni, Y, Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc.. 86. 1646
• Turner, CE, El Sohy, MA, Boeren, EG. (1989). Constituent of cannabis sativa L: A review of the natural constituent. Nat Procl.. 43. 169-234
• Freud, TR, Katona, I, Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev.. 83. 1017
• Matsuda, S, Kanemitsu, N, Nakamura, A, Mimura, Y, Ueda, N, Kurahashi, Y. (1997). Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp Eye Res.. 64. 707
• Bisogno, T, Delton-Vandenbroucke, I, Milone, A, Lagarde, M, Di Marzo, V. (1999). Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys.. 370. 300
• Glaser, ST, Deutsch, DG, Studholme, KM, Zimov, S, Yazulla, S. (2005). Endocannabinoids in the intact retina: 3H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide. Vis Neursoci.. 22. 693-705
• Chen, J, Matias, I, Dinh, T, Lu, T, Venezia, S, Nieves, A. (2005). Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun.. 330. 1062
• He, F, Song, ZH. (2007). Molecular and celular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol Vis.. 13. 1348
• Chien, FY, Wang, RF, Mittag, TW. (2003). Effects of WIN-55212-2, a cannabinoid receptor agonist, on aqueous humor dynamic in monkeys. Arch Ophthalmol.. 126. 498-505
• Struik, ML, Yazulla, S, Kamermans, M. (2006). Cannabinoid agonist WIN 55212-2 speeds up the cone response to light offset in goldfish retina. Vis Neurosci.. 23. 285
• Van der Stelt, M, Veldhuis, WB, van Haaften, GW, Fezza, F, Bisogno, T, Bar, PR. (2001). Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci.. 278. 157
• Matsuda, LA, Lolait, SJ, Brownstein, MJ, Young, AC, Bonner, TI. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346. 56156
• Munro, S, Thomas, KL, Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365. 61
• Breivogel, CS, Griffin, G, Di Marzo, V, Martin, BR. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol.. 60. 155
• Porcella, A, Casellas, P, Gessa, GL, Pani, L. (1998). Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain Res Mol Brain Res.. 58. 240
• Straiker, AJ, Maguire, G, Mackie, K, Lindsey, J. (1999). Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci.. 40. 2442
• Yazulla, S, Studholme, KM, McIntosh, HH, Deutsch, DG. (1999). Immunocytochemical localization of cannabinoid CB1 receptor and fatty acidamide hydrolase in rat retina. J Comp Neurol.. 415. 80-90
• Romano, MR, Lograno, MD. (2006). Cannabinoid agonists induce relaxation in the bovine ophthalmic artery for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol.. 147. 917
• Green, K. (1998). Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol.. 116. 1433
• Hepler, RS, Petrus, RJ. (1976). The therapeutic potential of marihuana. Plenum Publishing. New York.
• Cooler, P, Gregg, JM. (1976). The therapeutic potential of marihuana. Plenum Publishing. New York.
• Tomida, I, Azuara-Blanco, A, House, H, Flint, M, Pertwee, RG, Robson, PJ. (2006). Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 15. 349
• Naveh, N, Weissman, C, Muchtar, S, Benita, S, Mechoulam, R. (2000). A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Exp Ophthalmol.. 238. 334
• Porcella, A, Maxia, C, Gessa, GL, Pani, L. (2001). The synthetic cannabinoid WIN 55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J Neurosci.. 13. 409
• Stamer, WD, Golightly, SF, Hosohata, Y, Ryan, EP, Porter, AC, Varga, E. (2001). Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol.. 431. 277
• Colasanti, BK. (1990). A comparison of the ocular and central effects of delta-9-tetrahydrocannabinol and cannabigerol. J Ocular Pharmacol.. 6. 259
• Njie, YF, Kumar, A, Qiao, Z, Zhong, L, Song, Z-H. (2006). Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptor to enhance aqueous humor outflow facility. Invest Ophthalmol Vis Sci.. 47. 1999-2005
• ltmanns, MH, Samudre, SS, Castillo, IG, Hosseini, A, Lichtman, AH, Allen, RC. (2008). Topical WIN 55212-2 alleviates intraocular hypertension in rats through a CB1 receptor-mediated mechanism of action. J Ocul Pharmacol Ther.. 24. 104
• Devane, WA, Hanus, L, Breuer, A, Pertwee, RG, Stevenson, LA, Griffin, G. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258. 1946
• Beilin, M, Neumann, R, Belkin, M, Green, K, Bar-llan, A. (2000). Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid. J Ocul Pharmacol Ther.. 16. 217
• Howlett, AC, Bidaut-Russell, M, Devane, WA, Melvin, LS, Johnson, MR, Herkenham, M. (1990). The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci.. 13. 40
• Galve-Roperh, I, Aguado, T, Palazuelos, Y, Guzmán, M. (2008). Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des.. 14. 2279
• Marsicano, G, Goodenough, S, Monory, K, Hermann, H, Eder, M, Cannich, A. (2003). CB1 cannabinoid receptors on-demanmd defense against excitotoxicity. Science. 302. 84
• Khaspekov, LG, Brenz, MS, Frumkina, LE, Hermann, H, Marsicano, G, Lutz, B. (2004). Involvement of brain-derived neurotrophic factor in cannabinoid-dependent protection against excitotoxicity. Eur J Neurosci.. 19. 1691
• Molina-Holgado, E, Vela, JM, Arévalo-Martín, A, Almazán, G, Molina-Holgado, F, Borrell, J. (2002). Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci.. 22. 9742
• Eljaschewitsch, E, Witting, A, Mawrin, C, Lee, T, Schmidt, PM, Wolf, S. (2006). The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 49. 67-79
• Veldhuis, WB, van der Stelt, M, Wadman, MW, van Zadelhoff, G, Maccarrone, M, Fezza, F. (2003). Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxcity in the rat: role of vanilloid receptors and lipoxygenases. J Neurosci.. 23. 4127
• Liu, J, Wang, L, Harvey -White, J, Osei-Hyiaman, D, Razdam, R, Song, G. (2006). A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA. 103. 13345
• Vink, R, Nimmo, AJ. (2009). Multifunctional drugs for head injury. Neurotherapeutics. 6. 28-42
• Nucci, C, Tartaglione, R, Rombola, L, Morrone, LA, Fazzi, E, Bagetta, G. (2005). Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology. 26. 935
• Honkanen, RA, Baruah, S, Zimmerman, MB, Khanna, CL, Weaver, YK, Narkiewicz, J. (2003). Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol.. 121. 183
• El-Remessy, AB, Khalil, IE, Matragoon, S, Abou-Mohamed, G, Tsai, N-J, Roon, P. (2003). Neuroprotective effect of (-)D 9-tetrahydrocannabinol and cannabidiol in N-Methyl-D-Aspartate-induced retinal neurotoxicity. Am J Pathol.. 163. 1977-2008
• Sisk, DR, Kuwabara, T. (1985). Histologic changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamate. Graefes Arch Clin Exp Ophthalmol.. 223. 250
• Samy, CN, Lui, CJ, Kaiser, PK, Lipton, SA, Dreyer, EB. (1994). Toxicity of chronic glutamate administration to retina. Invest Ophthalmol Vis Sci.. 35. 497
• Glovinsky, Y, Quigley, HA, Pease, ME. (1993). Foveal ganglion cell loss is size dependent in experimental glaucoma. Invest Ophthalmol Vis Sci.. 34. 395-400
• Marsicano, G, Moosmann, B, Hermann, H, Lutz, B, Behlt, C. (2002). Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem.. 80. 448
• Twitchell, W, Brown, S, Mackie, K. (1997). Cannabinoids inhibit N- and P/Q-type calcium channel in cultured rat hyppocampal neurons. J Neurophysiol.. 78. 43-50
• Bisogno, T, Haus, L, De Petrocellis, L, Tchilibon, S, Ponde, DE, Brandi, I. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol.. 134. 845
• Sugiura, T, Kodaka, T, Nakane, S, Kishimoto, S, Kondo, S, Waku, K. (1998). Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator?. J Biochem Biophys Res Commun.. 243. 838
• Quigley, HA, Hohman, RM, Addicks, EM, Green, WR. (1984). Blood vessels of the glaucomatous optic disk in experimental primate and human eyes. Invest Ophthalmol Vis Sci.. 25. 918
• Hafez, AS, Bizzarro, RLG, Lesk, MR. (2003). Evaluation of optic nerve head and peripapillary retinal blood flow in glaucoma patients: Ocular hypertension and normal subjects. Am J Ophthalmol.. 136. 1022
• Mukhopadhyay, S, Chapnick, BM, Howlett, AC. (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol.. 282. 2046
• Merritt, JC. (1982). Glaucoma, hypertension and marijuana. J Natl Med Assoc.. 74. 715
• Plange, N, Arend, KO, Kaup, M, Doehmen, B, Adams, H, Hendricks, S. (2007). Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol.. 143. 173
• Green, K, Wynn, H, Padgett, D. (1978). Effects of delta-9-tetrahydrocannabinol on ocular blood flow and aqueous humor formation. Exp Eye Res.. 26. 65
• Rosenkrantz, H, Fleischman, RW. (1979). Marihuana: Biological effects. Pergamon Press. Elmsford^eNY NY.
• Pertwee, RG. (2000). Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp Opin Invest Drugs. 9. 1553
• Martín, BR. (1986). Cellular effects of cannabinoids. Pharmacolog Rev.. 38. 45-74
• Hodges, LC, Reggio, PH, Green, K. (1997). Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits. Ophthalmic Res.. 29. 1-5
• Colasanti, BK, Craig, CR, Allora, DR. (1984). Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res.. 39. 251
• Hosseini, A, Lattanzio, FA, Williams, PB, Tibbs, D, Samudre, SS, Allen, RC. (2006). Chronic topical administration of WIN-55212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. Exp Eye Res.. 82. 753
• Pate, DW, Järvinen, K, Urtti, A, Mahadevan, V, Järvienen, T. (1988). Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci.. 63. 2181
• Pate, DW, Järvinen, K, Urtti, A, Jarho, P, Fich, M, Mahadevan, V. (1996). Effects of topical anandamide on intraocular pressure in normotensive rabbits. Life Sci.. 58. 1849
• Green, K, Roth, M. (1982). Ocular effects of topical administration of delta 9-tetrahydrocannabinoid in man. Arch Ophthalmol.. 100. 265
• Yazulla, S. (2008). Endocannabinoids in the retina: from marihuana to neuroprotection. Prog Retin Eye Res.. 27. 501
• Pinar-Sueiro, S. (2009). Role of cannabinoids in glaucoma. Arch Soc Esp Oftalmol.. 84. 487
• Nucci, C, Bari, M, Spanò, A, Corasaniti, M, Bagetta, G, Maccarrone, M. (2008). Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure to neurprotection. Prog Brain Res.. 173. 451
• Candrall, J, Matragoon, S, Khalifa, YM, Borlogan, C, Tsai, NT, Caldwell, RB. (2007). Neuroprotective and intraocular pressure-lowering effects of (-)Delta-9-tetrahydrocannibol in a rat model of glaucoma. Ophthalmic Res.. 39. 69-75